Genomic Profiling Platforms: Choosing the Right Test for Your Practice

Why Genomic Profiling Matters in Modern Oncology

Comprehensive genomic profiling (CGP) employs next‑generation sequencing to interrogate hundreds of cancer‑related genes, copy‑number changes, fusions, microsatellite instability, and tumor mutational burden from a single tissue or liquid biopsy sample. By consolidating multiple biomarker assays into one test, CGP reduces tissue consumption, shortens turnaround time, and provides a panoramic view of the tumor’s molecular landscape, as highlighted by Illumina’s TruSight Oncology Comprehensive kit and FDA‑approved liquid‑biopsy assays such as FoundationOne Liquid CDx and Guardant360 CDx. This breadth enables the identification of actionable alterations—e.g., EGFR, KRAS G12C, BRCA1/2, NTRK fusions—that directly inform the selection of targeted therapies, immunotherapies, or clinical‑trial enrollment, thereby moving treatment from a one‑size‑fits‑all to a precision paradigm. For Hirschfeld Oncology, which specializes in pancreatic ductal adenocarcinoma, CGP is especially critical: KRAS mutations dominate, yet a subset harbors BRCA1/2, PALB2, or DNA‑repair defects that confer eligibility for PARP inhibitors, while rare NTRK fusions or high tumor mutational burden can open immunotherapy options. Implementing CGP in this setting maximizes the chance of uncovering these low‑frequency, high‑impact biomarkers, aligns with NCCN and ASCO recommendations for advanced solid tumors, and empowers patients with personalized therapeutic strategies that improve outcomes and quality of life.

Choosing Between Standard NGS and Comprehensive Genomic Profiling

Standard next‑generation sequencing (NGS) panels typically focus on a limited gene set or hotspot mutations, requiring separate assays for copy‑number alterations, fusions, microsatellite instability (MSI) or tumor mutational burden (TMB). In contrast, comprehensive genomic profiling (CGP) uses a single high‑throughput NGS assay to evaluate hundreds of cancer‑related genes, encompassing single‑nucleotide variants, indels, copy‑number alterations, gene fusions, splice variants and genomic signatures such as microsatellite instability (MSI) and tumor mutational burden (TMB). Because CGP consolidates all biomarker testing into one run, it conserves precious biopsy material and avoids iterative testing, often delivering results in 4–10 days for both tissue and liquid‑biopsy specimens. This broader coverage increases the likelihood of identifying actionable alterations, expanding eligibility for FDA‑approved targeted therapies, immunotherapies and genotype‑driven clinical trials—particularly in metastatic NSCLC, pancreatic and other advanced solid tumors where guidelines now recommend panel‑based testing.

What is the difference between standard NGS and comprehensive genomic profiling (CGP)?
Standard NGS panels usually target a limited set of genes or hotspot mutations, often requiring separate assays for different variant types or biomarkers. Comprehensive genomic profiling (CGP) employs a single, high‑throughput NGS assay that simultaneously evaluates hundreds of cancer‑related genes along with copy‑number alterations, gene fusions, splice variants, and genomic signatures such as tumor mutational burden and microsatellite instability. Because CGP consolidates testing into one multiplex assay, it conserves precious biopsy material, reduces turnaround time, and eliminates the need for iterative testing. The broader coverage increases the likelihood of identifying actionable alterations and eligibility for targeted therapies or clinical trials. In short, CGP provides a panoramic, nucleotide‑level view of a tumor’s genomic landscape, whereas standard NGS offers a narrower, gene‑by‑gene snapshot.

Technology Platforms Shaping Clinical Oncology

Illumina’s short‑read sequencers dominate clinical oncology. Bench‑top models such as the MiSeq i100 Series (up to 30 Gb, 4‑24 h run) enable targeted gene panels and RNA‑seq for small cohorts, while the NextSeq 550 (120 Gb, 11‑29 h) and NextSeq 1000/2000 (540 Gb, 8‑44 h) support larger panels, exomes, and single‑cell profiling. Production‑scale NovaSeq 6000 (up to 3 Tb) and NovaSeq X Series (8‑10.5 Tb) provide the depth required for whole‑genome, metagenomics, and cell‑free DNA liquid‑biopsy assays. Illumina’s remote technical support, onsite training, and rental programs facilitate adoption across institutions.

Thermo Fisher’s Ion Torrent family, especially Gene Studio S5 and the integrated Genexus platform, offers rapid, amplicon‑based cancer panels with fast turn‑around and automated library preparation, making them popular for quick mutation screening in clinical labs.

Long‑read technologies such as PacBio SMRT (HiFi reads) and Oxford Nanopore (MinION/GridION) are emerging for comprehensive structural‑variant detection, full‑length transcriptome analysis, and complex fusion discovery, complementing short‑read data when detailed genomic architecture is needed.

AI‑driven interpretation tools—e.g., Tempus’ Smart Reporting, Caris Life Sciences’ FOLFIRSTai™, and Illumina’s OncoKB‑integrated pipelines—automatically prioritize actionable alterations, predict resistance, and match patients to clinical trials, reducing the burden on molecular tumor boards and accelerating precision‑oncology decisions.

Which NGS platforms are most commonly used in clinical oncology? In clinical oncology the most widely adopted next‑generation sequencing platforms are Illumina’s short‑read systems, ranging from benchtop instruments such as the MiSeq and iSeq to high‑throughput models like NextSeq, NovaSeq and the NovaSeq X series, which provide the depth and accuracy needed for tumor‑gene panels, exomes and liquid‑biopsy assays. Thermo Fisher Scientific’s Ion Torrent family—particularly the GeneStudio S5 and the integrated Genexus sequencer—is also frequently used for rapid, amplicon‑based cancer panels because of its fast run times and ease of workflow automation. MGI’s DNBSEQ platforms (formerly Complete Genomics) are gaining traction in some labs for their high‑density nanoball sequencing and competitive cost per base. Long‑read technologies such as Pacific Biosciences’ SMRT sequencers and Oxford Nanopore’s MinION/GridION systems are increasingly employed for complex structural‑variant detection and full‑length transcript profiling, although they remain secondary to short‑read platforms for routine clinical testing. Together, these instruments cover the spectrum of oncology applications—from targeted mutation profiling and comprehensive tumor sequencing to circulating‑tumor‑DNA analysis—making them the core NGS tools in today’s cancer‑care landscape.

When to Use Whole‑Exome vs Whole‑Genome Sequencing

Whole‑exome sequencing (WES) and whole‑genome sequencing (WGS) each have distinct strengths that guide their clinical deployment.
WES targets the ~1.5 % of the genome that encodes proteins, delivering high‑depth coverage of known driver mutations at a lower cost and with manageable data volumes.
This makes WES the preferred first‑line test for many solid tumors where actionable alterations are typically coding variants, such as EGFR, KRAS, or BRAF mutations.
In contrast, WGS surveys both coding and non‑coding regions, capturing regulatory mutations, structural rearrangements, copy‑number changes, and complex fusions that WES may miss.
The broader coverage can raise diagnostic yield substantially—up to an additional 10‑20 % of clinically relevant alterations in refractory or rare cancers—enabling more precise therapeutic matching.
Cost and data‑management considerations are pivotal.
WGS is roughly 1.5–2× more expensive than WES, generates several terabytes of raw data per sample, and requires advanced bioinformatics pipelines and storage infrastructure.
WES, with smaller data sets, is faster to analyze and integrates more easily into routine pathology workflows.
Clinical scenarios favoring WES include early‑line profiling of common cancers where established biomarkers drive therapy.
WGS is favored for complex cases: tumors with low ctDNA shedding, cancers of unknown primary, or when prior WES fails to identify actionable targets.

Is whole‑genome sequencing (WGS) better than whole‑exome sequencing (WES) for cancer diagnostics?
Whole‑genome sequencing (WGS) provides a more comprehensive view of a tumor than whole‑exome sequencing (WES) because it captures both coding and non‑coding regions, allowing detection of regulatory mutations, structural rearrangements, and copy‑number alterations that WES can miss.
This broader coverage can increase diagnostic yield by up to 100 % in some studies, leading to more precise therapeutic matching and faster time to diagnosis.
However, WGS is typically 1.5–2 × more expensive, generates larger data sets, and requires more sophisticated bioinformatic pipelines and interpretation expertise.
For many solid tumors, especially when the primary drivers are well‑characterized coding mutations, WES remains a cost‑effective first‑line tool that still informs targeted therapy.
In practice, the choice hinges on clinical need, budget, and the availability of analytical resources, with WGS increasingly favored for complex or refractory cancers where a deeper genomic insight can change management.

Liquid Biopsy versus Tissue Biopsy for CGP

Liquid biopsy offers a minimally invasive sampling method for comprehensive genomic profiling (CGP). By analyzing circulating tumor DNA (ctDNA) or cell‑free DNA (cfDNA) from a simple blood draw, tests such as FoundationOne CDx (324‑gene panel) and Guardant360 CDx (55‑gene panel) can be performed without the pain, risk, or logistical challenges of traditional tissue biopsies. This approach shortens turnaround time, enables repeat sampling for disease monitoring, and is especially valuable when tumor tissue is scarce, inaccessible, or unsafe to obtain.

Despite these advantages, liquid‑biopsy CGP generally has lower analytical sensitivity than tissue‑based testing, particularly in early‑stage disease or when ctDNA shedding is low. Concordance studies report agreement rates for actionable mutations ranging from 48 % to 93 % between liquid and tissue assays, with tissue remaining the gold standard for highest sensitivity and the ability to assess histology and immunohistochemistry (e.g., PD‑L1). Liquid biopsies may miss low‑allele‑frequency variants but can capture tumor heterogeneity and resistance mutations that a single‑site tissue biopsy might overlook.

FDA‑approved liquid CGP assays, including FoundationOne CDx and Guardant360 CDx, are companion diagnostics for multiple solid tumors such as non‑small‑cell lung cancer, prostate, ovarian, and breast cancers. Their regulatory status underscores clinical validity and facilitates insurance reimbursement when indicated.

In the broader sequencing landscape, Oxford Nanopore technology is often favored over Illumina for applications requiring ultra‑long reads. Nanopore’s ability to generate reads spanning thousands to millions of bases enables the detection of structural variants, copy‑number changes, and repetitive regions that short‑read Illumina data may miss. Direct, of native DNA or RNA also captures epigenetic modifications and full‑length transcript isoforms, while real‑time output and portable devices such as the MinION provide rapid, on‑site results—features valuable for certain clinical and research settings despite slightly lower per‑base accuracy.

Economic and Practical Considerations

Cost ranges for cancer genomic testing vary widely by scope. Targeted single‑gene or hotspot panels typically cost $300–$3,000 per sample, while comprehensive genomic profiling (CGP) assays that assess hundreds of genes run $1,300–$5,000 (tissue‑based) to $4,700–$5,000 (liquid‑biopsy) in the United States. Whole‑exome sequencing (WES) is priced around $4,500 and whole‑genome sequencing (WGS) can exceed $8,000–$10,000 per case. Most private insurers and Medicare reimburse medically indicated tests, often leaving patients with $0–$250 out‑of‑pocket cost; many laboratories offer financial‑assistance programs or self‑pay rates as low as $250 for uninsured individuals. Budget‑impact models show that replacing single‑gene assays with comprehensive genomic profiling (CGP) raises health‑system expenditures (e.g., $4.4 million–$37 million over three years for NSCLC in Ontario) but adds hundreds of life‑years, suggesting a trade‑off between higher upfront costs and downstream survival benefits. Implementing comprehensive genomic profiling (CGP) requires specialized labs, bioinformatics pipelines, and multidisciplinary tumor boards, which further affect system budgets. Overall, the economic picture balances higher test costs and infrastructure needs against the potential for more precise therapy selection, improved outcomes, and long‑term cost‑effectiveness as targeted therapies become more widely available.

Clinical Utility and Benefits of Comprehensive Genomic Profiling

Comprehensive genomic profiling (CGP) evaluates hundreds of cancer‑related genes and key biomarkers such as tumor mutational burden, microsatellite instability and homologous recombination deficiency in a single assay. This breadth allows rapid identification of actionable alterations—including single‑nucleotide variants, indels, copy‑number changes, gene fusions, and splice variants—often missed by single‑gene or hotspot panels. By coupling DNA and RNA analysis, or using liquid‑biopsy platforms (e.g., FoundationOne Liquid CDx, Guardant360 CDx), CGP captures both tissue‑based and circulating tumor DNA, providing a more complete view of tumor heterogeneity and resistance mechanisms.

The molecular findings are directly linked to FDA‑approved targeted therapies, off‑label options, and tumor‑agnostic agents, enabling therapeutic matching and enrollment in genotype‑driven clinical trials. Real‑world studies of large CGP cohorts (e.g., >50,000 patients) show that patients receiving matched therapy have longer progression‑free and overall survival—median OS gains of 5–6 months in several tumor types—and higher trial enrollment rates. Multidisciplinary molecular tumor boards increase the likelihood of actionable treatment decisions, reinforcing CGP’s role as a cornerstone of precision oncology and personalized care planning.

Genetic Markers and Testing Strategies in the United States

Comprehensive genomic profiling (CGP) using next‑generation‑ (NGS) panels is the preferred genetic testing strategy for cancer patients in the United States. A CGP assay evaluates hundreds of cancer‑related genes in a single tumor (somatic) sample and, when indicated, adds germline DNA to capture inherited risk. Ordering a multigene panel through a CAP‑ and CLIA‑certified laboratory (e.g., Ambry, Myriad, Invitae) ensures analytical accuracy, rapid turnaround, and insurance coverage. Pre‑ and post‑test genetic counseling is essential for interpreting results and addressing family risk.

Commonly sequenced driver genes include KRAS, NRAS, BRAF, EGFR, HER2, ALK, ROS1, TP53, PIK3CA, and CDKN2A. Mismatch‑repair genes (MLH1, MSH2, MSH6, PMS2) are tested for microsatellite instability, while hereditary cancer genes such as BRCA1/2, APC, and PTEN guide PARP‑inhibitor eligibility and familial screening.

Guideline‑driven panel selection follows NCCN and ASCO recommendations. For metastatic NSCLC and other advanced solid tumors, broad panel‑based NGS (≥300 genes) is advised when tissue is adequate; liquid‑biopsy CGP (e.g., FoundationOne Liquid CDx, Guardant360 CDx) is used when tissue is insufficient. Panel size is balanced against tumor accessibility, turnaround time, and cost.

Integration of somatic and germline testing is critical because tumor‑only profiling can miss up to 10 % of pathogenic germline variants. When a somatic report identifies a hereditary cancer‑related gene (e.g., BRCA1/2, MLH1), reflex germline testing is recommended, often coordinated through a molecular tumor board.

Answers to key questions

• Best approach: CGP with both somatic and germline analysis, performed in a CLIA‑certified lab and supported by genetic counseling.
• Most common markers: KRAS, NRAS, BRAF, EGFR, HER2, ALK, ROS1, TP53, PIK3CA, CDKN2A, MLH1, MSH2, MSH6, PMS2, BRCA1/2, APC, PTEN.
• Accuracy: Validated NGS panels achieve >99 % sensitivity for SNVs and >95 % for indels; germline panels >98 % for high‑penetrance genes, with low false‑positive rates when bioinformatics filters and confirmatory testing are applied.

Future Directions and Emerging Technologies

Long‑read sequencing (e.g., Oxford Nanopore, PacBio) now resolves complex structural variants, repeat‑rich regions, and gene fusions that short‑read panels miss, expanding actionable insight in cancers such as pancreatic adenocarcinoma. AI‑driven interpretation platforms—Tempus Smart Reporting, Caris FOLFIRSTai, and others—automatically prioritize variants, suggest FDA‑approved therapies or trials, and flag resistance, compressing data‑to‑decision time. Integrated multi‑omic profiling that couples DNA‑seq, RNA‑seq, and protein/IHC data delivers a holistic tumor view, enabling simultaneous assessment of mutations, expression‑driven fusions, microsatellite instability, and tumor mutational burden.

Is Illumina sequencing more accurate than Sanger sequencing? Sanger remains the gold‑standard for single‑locus testing with >99 % per‑base accuracy. Illumina’s NGS has a higher raw error per read, but deep (>100×) coverage raises consensus accuracy to >99.9 % across millions of bases, providing genome‑wide precision that equals or exceeds Sanger while offering greater throughput and cost per base. In oncology, Illumina is preferred for profiling, with Sanger used mainly for confirmatory testing.

Putting It All Together for Your Practice

Key takeaways for test selection: prioritize broad NGS panels (CGP) when tissue is adequate, use FDA‑approved liquid‑biopsy CGP (e.g., FoundationOne Liquid CDx, Guardant360 CDx) for inaccessible tumors, and match panel size to clinical need and guideline‑recommended biomarkers (EGFR, KRAS, MSI, TMB). Implementation roadmap for a multidisciplinary team: assemble oncologists, pathologists, molecular tumor‑board members, and genetic counselors; establish CLIA‑certified, CAP‑accredited labs (Illumina NovaSeq/X, TruSight Oncology Comprehensive); create SOPs for sample handling, bioinformatics pipelines, and rapid turn‑around (≤10 days). Ensuring patient‑centered, data‑driven care: obtain informed consent, educate patients on the benefits of minimally invasive liquid biopsies, integrate CGP reports into EHR‑based decision support, and use AI‑augmented platforms (Tempus, Caris) to match actionable alterations to FDA‑approved therapies or trials while monitoring outcomes for continuous quality improvement.